NeoChord company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Convertible Note - II | Alive

Total Raised


Last Raised

$1.75M | 3 mos ago

About NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.

NeoChord Headquarter Location

5402 Parkdale Drive Suite 160

Minneapolis, Minnesota, 55416,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing NeoChord

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NeoChord is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,082 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,900 items

NeoChord Patents

NeoChord has filed 28 patents.

The 3 most popular patent topics include:

  • Cardiac surgery
  • Cardiology
  • Cardiac anatomy
patents chart

Application Date

Grant Date


Related Topics




Cardiac anatomy, Cardiac surgery, Cardiology, Valvular heart disease, Implants (medicine)


Application Date


Grant Date



Related Topics

Cardiac anatomy, Cardiac surgery, Cardiology, Valvular heart disease, Implants (medicine)



Latest NeoChord News

NeoChord appoints executive chair to lead early feasibility study of transcatheter mitral chordal repair device

Mar 15, 2022

Medical Tubing and Extrusion Search this website March 15, 2022 NeoChord appointed Dr. Martin Leon as executive chair of the company’s U.S. early feasibility study of its Transcatheter Nexus system. Leon will be responsible for overseeing and leading the company’s initiatives to advance its U.S. regulatory strategy for the Nexus system. He will also guide the company’s overall global regulatory strategy as it continues to enroll patients in its European early feasibility study (EFS). “As a preeminent thought leader and innovator in the field of interventional cardiology, we are excited to collaborate with Dr. Leon ahead of the anticipated launch of our U.S. early feasibility study later this year,” President and CEO David Chung said in a news release  yesterday. “We continue to see exceptionally strong clinical results from early cases conducted as part of our European study, and we are excited to move forward with our initiatives in the U.S. to advance down the regulatory pathway towards eventual FDA approval.” NeoChord designed its Nexus transcatheter mitral chordal repair device to restore function in patients with severe symptomatic primary mitral regurgitation, which happens when blood leaks backward within the heart. “I look forward to working with the NeoChord team as executive chair of this early feasibility study in the U.S., particularly given the exciting potential of the Nexus transcatheter mitral repair technology,” Leon said. “I believe the Nexus system is uniquely designed to restore normal function via a minimally invasive approach for many patients with severe symptomatic primary mitral regurgitation and therefore may emerge as a technology category disrupting front-line therapy.” Leon is the Mallah Family professor of cardiology and director of Columbia Interventional Cardiovascular Care at Columbia University Irving Medical Center. He is also the director of the Center for Interventional Vascular Therapy, Cardiac Catheterization Laboratories and the executive board of the New York-Presbyterian University Hospital of Columbia and Cornell Heart & Valve Center. Leon is the founder and chairperson of the annual Transcatheter Cardiovascular Therapeutics (TCT) conference.

NeoChord Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

NeoChord Rank

  • When was NeoChord founded?

    NeoChord was founded in 2007.

  • Where is NeoChord's headquarters?

    NeoChord's headquarters is located at 5402 Parkdale Drive, Minneapolis.

  • What is NeoChord's latest funding round?

    NeoChord's latest funding round is Convertible Note - II.

  • How much did NeoChord raise?

    NeoChord raised a total of $86.92M.

  • Who are NeoChord's competitors?

    Competitors of NeoChord include EBR Systems, Vertos Medical, SynCardia Systems, Ancora Heart, Corassist Cardiovascular, Cardiva Medical, Benvenue Medical, Cardiac Dimensions, IntraOp Medical, Angel Medical Systems and 75 more.

You May Also Like


CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.

Arbor Surgical Technologies

Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.

Transoma Medical

Transoma Medical remotely measures heart function in animals and humans.

Cardiac Dimensions Logo
Cardiac Dimensions

Cardiac Dimensions develops minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company's initial technology platform, the CARILLON Mitral Contour System has been designed to address functional mitral regurgitation, utilizing a novel percutaneous approach. Cardiac Dimensions has operations in Kirkland, Washington; Sydney, Australia and Frankfurt, Germany.

Mitralign Logo

Mitralign is developing a catheter-based technology for percutaneous treatment of functional mitral regurgitation. The Mitralign system emulates surgical annuloplasty delivering a series of surgical implants directly into the mitral annulus by means of a catheter. The implants are cinched together, thus reducing the size of the mitral valve annulus and the valve opening.

Ancora Heart Logo
Ancora Heart

Ancora Heart is developing a therapy to address heart failure. Ancora Heart's AccuCinch Ventricular Repair System is a minimally invasive investigational treatment for heart failure and functional mitral regurgitation (FMR).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.